References
- DhillonSKeatingGMLutropin alfaDrugs200868111529154018627209
- DurocherYButlerMExpression systems for therapeutic glycoprotein productionCurr Opin Biotechnol200920670070719889531
- le CotonnecJYPorchetHCBeltramiVKhanAToonSRowlandMClinical pharmacology of recombinant human follicle-stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSHFertil Steril19946146696788150109
- ChambostHLjungRChanging pattern of care of boys with haemophilia in western European centresHaemophilia2005112929915810909
- DayaSFollicle-stimulating hormone in clinical practice: an updateTreat Endocrinol20043316117116026112
- van WelyMKwanIBurtALRecombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cyclesCochrane Database Syst Rev20112CD00535421328276
- Recombinant Human FSH Product Development GroupRecombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertilityHum Reprod Update19984686288110098477
- HuirneJALambalkCBvan LoenenACContemporary pharmacological manipulation in assisted reproductionDrugs200464329732214871171
- ReichlHBalenAJansenCAPrion transmission in blood and urine: what are the implications for recombinant and urinary-derived gonadotrophins?Hum Reprod200217102501250812351519
- HarrisonSWolfTAbuzeidMIAdministration of recombinant follicle stimulating hormone in a woman with allergic reaction to menotropin: a case reportGynecol Endocrinol200014314915210923273
- EscobarMAHealth economics in haemophilia: a review from the clinician’s perspectiveHaemophilia201016Suppl 3293420586799
- European Medicines AgencyOvaleap (follitropin alfa) [assessment report]7312013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002608/WC500152908.pdfAccessed February 25, 2015
- Gonal-f® [summary of product characteristics]London, UKEuropean Medicines Agency2010
- Puregon [summary of product characteristics]London, UKEuropean Medicines Agency2006
- Bemfola (follitropin alfa) [summary of product characteristics]London, UKEuropean Medicines Agency2014
- MattaWHShawRWBurfordGDEndocrinologic and clinical evaluation following a single administration of a gonadotrophin-releasing hormone agonist (Zoladex), in a depot formulation, to premenopausal womenFertil Steril19884911631652961621
- Gonal-f® 75 IU (5.5 micrograms) powder and solvent for solution for injection [package insert]London, UKMerck Serono Europe Ltd2012
- le CotonnecJYPorchetHCBeltramiVKhanAToonSRowlandMClinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokineticsFertil Steril19946146796868150110
- LuganIFebbraroSLecuelleHPapasouliotisOHo-NguyenaQBuraglioMBioequivalence of liquid and freeze-dried recombinant human follicle-stimulating hormoneCurr Med Res Opin200521112112515881483
- GertzBLammerichAPhase I Study to establish the bioequivalence of recombinant human follicle stimulating hormone (r-hFSH; XM17) to Gonal-f® (follitropin alfa) in downregulated healthy female subjectsAbstract presented at the 10th Congress of the European Society of GynecologySeptember 18–21, 2013Brussels, Belgium
- GertzBBiasPLammerichAPhase I dose-ranging study of a recombinant human follicle-stimulating hormone (rhFSH) in healthy female volunteersHum Reprod201429Suppl 1i319i320 Abstr P-486